VR Logo

Dicerna Pharmaceuticals Inc (DRNA) download report


Healthcare | Biotechnology & Pharma Research

Dicerna Pharmaceuticals Inc (DRNA) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals.

IPO Date: 30-Jan-2014

Co-Founder, CEO, Pres & Director: Dr. Douglas M. Fambrough III

Chief Financial Officer: Mr. Douglas W. Pagan

Listing: NASDAQ: DRNA

Country: United States

Headquarters: Lexington, MA

Website: https://dicerna.com

Key Facts

Market cap: $2,977.70 Mln

Revenue (TTM): $192.85 Mln

Earnings (TTM): $-124.44 Mln

Cash: $565.51 Mln

Total Debt: $64.42 Mln

Insider's Holding: 7.43%

Liquidity:

52 Week range: $19.06 - 40.14

Shares outstanding: 77,909,504

10 Years Aggregate:

  • CFO: $-20.47 Mln
  • EBITDA: $-574.61 Mln
  • Net Profit: $-589.59 Mln

Stock Performance

Time Period Dicerna Pharmaceuticals Inc (DRNA) S&P BSE Sensex* *
YTD73.49-8.62--
1 month0.61-4.54--
3 months90.53-10.19--
1 Year71.541.43--
3 Years53.1510.14--
5 Years66.0211.26--
10 Years--11.82--
As on 29-Dec-2021 *As on 04-Jul-2022
Year Dicerna Pharmaceuticals Inc (DRNA) S&P BSE Sensex S&P BSE Sensex
202173.4921.9921.99
20200.0015.7515.75
2019106.0814.3814.38
201818.275.875.87
2017213.5427.9127.91
2016-75.741.951.95
2015-27.93-5.03-5.03